Clinical Trials Directory

Trials / Completed

CompletedNCT06315699

Clemastine Fumarate in the Treatment of Neurodevelopmental Delays in Williams Syndrome

Randomized, Double-blind, Controlled Study of Clomastine Fumarate in the Treatment of Williams Syndrome

Status
Completed
Phase
Phase 2
Study type
Interventional
Enrollment
28 (actual)
Sponsor
Qilu Hospital of Shandong University · Academic / Other
Sex
All
Age
3 Years – 12 Years
Healthy volunteers
Not accepted

Summary

This study focuses on therapeutic targets for cognitive, motor, and social impairments in Williams syndrome by reversing brain myelin defects caused by GTF2I. The primary objective of the study was to test and evaluate the initial efficacy and safety of Clomastine fumarate in the treatment of Williams syndrome.

Detailed description

The primary objective of this study was to evaluate the initial efficacy and safety of Clomastine fumarate in the treatment of Williams syndrome. The secondary objective is to study Clomastine fumarate in relation to mechanisms of action, safety, and/or pathological mechanisms. This study was a randomized, cross-over, placebo-controlled design. Each participant will be randomly assigned to two groups through baseline assessment (see study results), with Group A receiving the FDA-approved drug Clemastine at a weight-dependent dose (see dosing table below) for the first cycle and placebo for the second cycle. Group B will be treated with placebo for the first cycle and the FDA-approved drug Clemastine for the second cycle.

Conditions

Interventions

TypeNameDescription
DRUGClemastine Fumarate Tabletsclemastine fumarate (0.178 mg/kg/day), three months
DIETARY_SUPPLEMENTcorn starch tabletsThe dose was administered 2mg once daily in a double-blind random crossover method

Timeline

Start date
2024-03-20
Primary completion
2025-03-02
Completion
2025-12-30
First posted
2024-03-18
Last updated
2026-03-19

Locations

1 site across 1 country: China

Regulatory

Source: ClinicalTrials.gov record NCT06315699. Inclusion in this directory is not an endorsement.

Clemastine Fumarate in the Treatment of Neurodevelopmental Delays in Williams Syndrome (NCT06315699) · Clinical Trials Directory